Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Masuda S, Osawa R, Hosokawa N, Nakashima K, Kamura H, Imura H, Inoue H, Matsuzaka S, Sugimoto Y, Kuwamitsu O, Motohashi I, Morikawa T, Oda R, Hoshina Y, Matono T, Teshigahara O, Sando E, Asami S, Kudo S, Akizuki N, Muto Y, Hayakawa T, Kishaba T, Ohara Y, Kubo Y, Suzuki M, Morimoto K. Maeda H, et al. Among authors: nakashima k. Expert Rev Vaccines. 2024 Jan-Dec;23(1):213-225. doi: 10.1080/14760584.2024.2310807. Epub 2024 Feb 8. Expert Rev Vaccines. 2024. PMID: 38288980 Free article.
Recurrent pneumonia among Japanese adults: disease burden and risk factors.
Ishifuji T, Sando E, Kaneko N, Suzuki M, Kilgore PE, Ariyoshi K, Morimoto K, Hosokawa N, Yaegashi M, Aoshima M; Adult Pneumonia Study Group - Japan (APSG-J). Ishifuji T, et al. BMC Pulm Med. 2017 Jan 11;17(1):12. doi: 10.1186/s12890-016-0359-1. BMC Pulm Med. 2017. PMID: 28077107 Free PMC article.
Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
Nakashima K, Aoshima M, Ohfuji S, Yamawaki S, Nemoto M, Hasegawa S, Noma S, Misawa M, Hosokawa N, Yaegashi M, Otsuka Y. Nakashima K, et al. Hum Vaccin Immunother. 2018;14(8):1923-1930. doi: 10.1080/21645515.2018.1455476. Epub 2018 May 14. Hum Vaccin Immunother. 2018. PMID: 29561248 Free PMC article. Clinical Trial.
Six underlying health conditions strongly influence mortality based on pneumonia severity in an ageing population of Japan: a prospective cohort study.
Hamaguchi S, Suzuki M, Sasaki K, Abe M, Wakabayashi T, Sando E, Yaegashi M, Morimoto S, Asoh N, Hamashige N, Aoshima M, Ariyoshi K, Morimoto K; Adult Pneumonia Study Group – Japan. Hamaguchi S, et al. BMC Pulm Med. 2018 May 23;18(1):88. doi: 10.1186/s12890-018-0648-y. BMC Pulm Med. 2018. PMID: 29792181 Free PMC article.
Severe Community-acquired Pneumonia Caused by Acinetobacter baumannii Successfully Treated with the Initial Administration of Meropenem Based on the Sputum Gram Staining Findings.
Iwasawa Y, Hosokawa N, Harada M, Hayano S, Shimizu A, Suzuki D, Nakashima K, Yaegashi M. Iwasawa Y, et al. Among authors: nakashima k. Intern Med. 2019 Jan 15;58(2):301-305. doi: 10.2169/internalmedicine.0787-18. Epub 2018 Sep 12. Intern Med. 2019. PMID: 30210104 Free PMC article.
Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.
Nakashima K, Ishida M, Matsui H, Yoshida C, Nagai T, Shiraga M, Nakaoka H, Otsuka Y, Nakagama Y, Kaku N, Nitahara Y, Kido Y, Hirota Y. Nakashima K, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2140549. doi: 10.1080/21645515.2022.2140549. Epub 2022 Nov 11. Hum Vaccin Immunother. 2022. PMID: 36369871 Free PMC article.
2,835 results